Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients

Journal of Clinical Pharmacology

Volumn 53, Issue 8, 2013, Pages 827-833

  Mostafa Hedeab, Gomaa ^a,b   Saber Ayad, Maha M ^c,d   Latif, Inas A ^c   Elkashab, Sahier O ^c   Elshaboney, Tarek H ^c   Mostafa, Magdy Ibrahim ^c   El Shafy, Sanaa Abd ^a   Zaki, Magda M ^c  

^a BENI SUEF UNIVERSITY   (Egypt)

^b Misurata University   (Libyan Arab Jamahiriya)

^c Cairo University   (Egypt)

^d UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

Cyclosporine; MDR 1 gene polymorphisms; P glycoprotein; Pharmacogenetics; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DILTIAZEM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VERAPAMIL;

ABCB I GENE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; EXON; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY TRANSPLANTATION; MALE;

CYCLOSPORINE; MDR-1 GENE POLYMORPHISMS; P-GLYCOPROTEIN; PHARMACOGENETICS; RENAL TRANSPLANTATION;

CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84885029873     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.105     Document Type: Article

References (31)

1. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet. 2006;7:223-245. (Pubitemid 44627929)
2. Colombo D, Ammirati E. Cyclosporine in transplantation-a history of converging timelines. J Biol Regul Homeost Agents. 2011;25 (4):493-504.
3. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis. 2001;38(6):S25-35. (Pubitemid 34184670)
4. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant. 2002;2(8):789- 795. (Pubitemid 36342623)
5. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27(2-3):201-214. (Pubitemid 27417873)
6. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Sem Cancer Biol. 1997;8:135-142. (Pubitemid 28041010)
7. de Lannoy IA, Silverman M. The MDR1 gene product, Pglycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun. 1992;189(1):551-557. (Pubitemid 23030076)
8. Kaplan B, Lown K, Craig R, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplantation recipients: Possible Relationship to Intestinal Pglycoprotein Activity. Transplantation. 1999;67(2):333-335. (Pubitemid 29066365)
9. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal Pglycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62(3):248-260. (Pubitemid 27417790)
10. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 2000; 97:3473-3478. (Pubitemid 30183327)
11. Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology. 2002;27(181- 182):299-303. (Pubitemid 36015717)
12. Einecke G, Mai I, Diekmann F, et al. Cyclosporine absorption profiling and therapeutic drugmonitoring using C(2) blood levels in stable renal allograft recipients. Transplant Proc. 2002;34(5):1738-1739.
13. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotyperelated pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001;18:1400-1404. (Pubitemid 32977244)
14. Evans W, Relling MV. Pharmacogenomics. Translating functional genomics int o rational therapeutics. Science. 1999;286:487-491.
15. Dany A, Thervet E, Etienne I, et al. CYP3A5 and MDRl genetic polymorphisms and cyclosporine pharmacokineit cs after renal transplantation. Clin Pharmacol Ther. 2004;75(5):422-433. (Pubitemid 38534563)
16. Ameyaw M, Regateiro F, Li T, et al. MDR-1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11:217-221. (Pubitemid 32319871)
17. Jamroziak K, Balcerczak E, Mlynarski W, Mirowski M, Rob T. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDRl gene in a sample of Polish population. Pol J Pharmacol. 2002;54:495-500. (Pubitemid 35214975)
18. Xu LG, Xu HM, Zhang JR, Song QZ, Qi XP, Wang XH. Effects of different dosages of cyclosporine A on the semen parameters of renal transplant patients. Zhonghua Nan Ke Xue (English Version). 2003;9:679-683.
19. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199. (Pubitemid 32777772)
20. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55(6):560-569. (Pubitemid 36783197)
21. Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal Pglycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002;72:572-583. (Pubitemid 36237729)
22. Johne A, Köpke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002;72(5):584-594. (Pubitemid 36237730)
23. Zhang YT, Yang LP, Shao H, Li KX, Sun CH, Shi LW. ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. Br J Clin Pharmacol. 2008;66(2):240-246.
24. Von Ahsen N, Michael R, Michael O, Clemens G, Burckhardt R, Victor W. Armstrong. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4- V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47(6):1048-1052. (Pubitemid 32493590)
25. Mai I, Elke S, Mark G, et al. MDRl haploiypcs do noi aflect ihisieady-state pharmacokinetics of cyclosporine in renal transplani patients. J Clin Pharmacol. 2003;43(10):1101-1107.
26. Dogruer D, Tug E, Bes C, et al. Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. Genet Mol Res. 2013;24:12 (AOP). [Epub ahead of print].
27. Ruth A, Stein WD, Rose E, et al. Coordinate changes in drug resistance and drug-induced conformational transitions in alteredfunction mutants of the multidrug transporter P-glycoprotein. Biochemistry. 2001;40(14):4332-4339. (Pubitemid 32319579)
28. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008;325(2):435-442. (Pubitemid 351574805)
29. Sai K, Itoda M, Saito Y, et al. Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences. Ann Hum Genet. 2006;70(Pt 5):605-622. (Pubitemid 44173372)
30. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15(10):693-704. (Pubitemid 41345321)
31. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794(5):860-871.